Toxicological and clinical computational analysis and the US FDA/CDER.
In this article the author attempts to introduce those not familiar with computational toxicology to some of the terminology and basic principles of the field. The author then reports on the progress that the FDA, Center for Drug Evaluation and Research has made in compiling databases of toxicological and clinical data from which successful predictive toxicology models have been made, many of which are now commercially available through FDA software developer collaborators. This report is concluded with the author's personal speculations on the future of computational toxicology in general, and at US FDA in particular.
Benz
R Daniel
RD
US Food and Drug Administration, Office of Pharmaceutical Science, Center for Drug Evaluation and Research, 10903 New Hampshire Ave., Silver Spring, MD 20993, USA. R.Daniel.Benz@fda.hhs.gov
D000818:Animals; D003198:Computer Simulation; D019992:Databases as Topic; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D008962:Models, Theoretical; D004364:Pharmaceutical Preparations / Q000737:chemistry; D021281:Quantitative Structure-Activity Relationship; D014116:Toxicology / Q000379:methods*; D014481:United States; D014486:United States Food and Drug Administration
D004364:Pharmaceutical Preparations